Literature DB >> 35388227

The pharmacokinetics and pharmacodynamics of midazolam after intravenous administration to donkeys (Equus africanus asinus).

Odette O1, Bradley T Simon1, Lisa S Ebner1, Ignacio Lizarraga1, Xiaocun Sun1, Sherry K Cox1.   

Abstract

The pharmacokinetics and pharmacodynamics of midazolam were studied in eight 1-to-3-year-old healthy gelded donkeys. Blood samples were obtained. Heart rate, respiratory rate, rectal temperature, sedation/excitement, ataxia, and response to tactile and auditory stimuli were recorded at baseline until 48 hours after intravenous (IV) midazolam (0.1 mg/kg) administration. Plasma midazolam and 1-hydroxymidazolam were measured using reversed-phase high-performance liquid chromatography. Pharmacokinetic variables were calculated using non-compartmental analysis. Physiologic data were analyzed using a mixed-effects model followed by Dunnett's test and behavioral data were analyzed using a Friedman test then a Dunn's test; P < 0.05 was considered significant. Midazolam was detectable for up to 60 minutes post-treatment in 7 donkeys. The median total body clearance, volume of distribution at steady state, elimination half-life, and area under concentration-time profile were 1210 mL/kg/h, 359 mL/kg, 0.27 hours, and 82.7 h × ng/mL, respectively. 1-hydroxymidazolam was detected (29 to 105 ng/mL) between 5 to 15 minutes post-treatment in 4 donkeys. Compared to baseline, rectal temperature and ataxia increased from 90 to 720 minutes (P ≤ 0.038) and 3 to 15 minutes (P ≤ 0.024) post-treatment, respectively. No other parameters showed statistically significant differences. Healthy donkeys cleared midazolam rapidly from plasma after IV administration. Transient ataxia and recumbency without sedation were observed. Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35388227      PMCID: PMC8978292     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   0.897


  33 in total

1.  Pharmacokinetics of gentamicin in donkeys.

Authors:  R E Welfare; K L Mealey; N S Matthews; T S Taylor
Journal:  J Vet Pharmacol Ther       Date:  1996-04       Impact factor: 1.786

2.  Sedative-hypnotic effects of midazolam in goats after intravenous and intramuscular administration.

Authors:  G F Stegmann; L Bester
Journal:  Vet Anaesth Analg       Date:  2016-11-15       Impact factor: 1.648

3.  The pharmacokinetics of midazolam after intravenous, intramuscular, and rectal administration in healthy dogs.

Authors:  M Schwartz; K R Muñana; J A Nettifee-Osborne; K M Messenger; M G Papich
Journal:  J Vet Pharmacol Ther       Date:  2012-12-19       Impact factor: 1.786

4.  Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses.

Authors:  Kenneth E Peck; Nora S Matthews; Tex S Taylor; Katrina L Mealey
Journal:  Am J Vet Res       Date:  2002-03       Impact factor: 1.156

5.  Induction of anesthesia and recovery in donkeys sedated with xylazine: a comparison of midazolam-alfaxalone and midazolam-ketamine.

Authors:  Jill K Maney; H Edward Durham; Kathleen P Goucher; Erika L Little
Journal:  Vet Anaesth Analg       Date:  2018-04-16       Impact factor: 1.648

6.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

Authors:  K E Thummel; D D Shen; T D Podoll; K L Kunze; W F Trager; P S Hartwell; V A Raisys; C L Marsh; J P McVicar; D M Barr
Journal:  J Pharmacol Exp Ther       Date:  1994-10       Impact factor: 4.030

7.  Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs.

Authors:  M H Court; D J Greenblatt
Journal:  J Vet Pharmacol Ther       Date:  1992-12       Impact factor: 1.786

8.  Sedative and mechanical hypoalgesic effects of butorphanol in xylazine-premedicated donkeys.

Authors:  I Lizarraga; F Castillo-Alcala
Journal:  Equine Vet J       Date:  2014-05-28       Impact factor: 2.888

9.  Differential depression of neuronal network activity by midazolam and its main metabolite 1-hydroxymidazolam in cultured neocortical slices.

Authors:  Monika Balk; Harald Hentschke; Uwe Rudolph; Bernd Antkowiak; Berthold Drexler
Journal:  Sci Rep       Date:  2017-06-14       Impact factor: 4.379

10.  Evaluation of the use of midazolam as a co-induction agent with ketamine for anaesthesia in sedated ponies undergoing field castration.

Authors:  A Allison; R Robinson; C Jolliffe; P M Taylor
Journal:  Equine Vet J       Date:  2017-09-29       Impact factor: 2.888

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.